cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Essa Pharma Inc
14 own
46 watching
Current Price
$6.65
$-0.42
(-5.94%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
139.77M
52-Week High
52-Week High
11.67000
52-Week Low
52-Week Low
2.56000
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization139.77M
icon52-Week High11.67000
icon52-Week Low2.56000
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio--
What does the Essa Pharma Inc do?
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Read More
How much money does Essa Pharma Inc make?
News & Events about Essa Pharma Inc.
CNW Group - News Releases
1 year ago
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer Canada NewsWire SOUTH SAN...
PR Newswire
1 year ago
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer PR Newswire SOUTH SAN...
Ticker Report
1 year ago
ESSA Pharma Inc. (NASDAQ:EPIX Get Rating) (TSX:EPI) Research analysts at Oppenheimer issued their Q1 2024 earnings per share (EPS) estimates for ESSA Pharma in a note issued to investors on Tuesday, February 7th. Oppenheimer analyst M. Breidenbach expects that the company will post ...
PR Newswire
1 year ago
Thinking about buying stock in ESSA Pharma, Meta Platforms, Nio, Quanergy Systems, or Alphabet? Thinking about buying stock in ESSA Pharma, Meta Platforms, Nio, Quanergy Systems, or Alphabet? PR Newswire NEW YORK, Oct. 28, 2022 NEW YORK, Oct. 28, 2022 /PRNewswire/ -- InvestorsObserverissues...
Zolmax
1 year ago
Woodline Partners LP increased its stake in shares of ESSA Pharma Inc. (NASDAQ:EPIX Get Rating) (TSX:EPI) by 286.6% in the 4th quarter, HoldingsChannel reports. The firm owned 684,247 shares of the companys stock after buying an additional 507,239 shares during the quarter. Woodline Partners LPs ...
Frequently Asked Questions
Frequently Asked Questions
What is Essa Pharma Inc share price today?
plus_minus_icon
Can Indians buy Essa Pharma Inc shares?
plus_minus_icon
How can I buy Essa Pharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Essa Pharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Essa Pharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Essa Pharma Inc?
plus_minus_icon
What is today’s market capitalisation of Essa Pharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Essa Pharma Inc?
plus_minus_icon
What percentage is Essa Pharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Essa Pharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$6.65
$-0.42
(-5.94%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00